Clinical-stage pharmaceutical company Plus Therapeutics Inc (Nasdaq:PSTV) announced on Thursday that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Rhenium (186Re) Obisbemeda for treating leptomeningeal metastases (LM) in lung cancer patients.
LM is a rare and fatal cancer complication where tumour cells spread to the cerebrospinal fluid and leptomeninges surrounding the brain and spinal cord. It affects approximately 5% of cancer patients, with survival rates of 7% at one year and 3% at two years. There are currently no FDA-approved treatments for LM.
Rhenium (186Re) Obisbemeda is an injectable radiotherapy designed to deliver targeted radiation to central nervous system tumours.
The FDA's ODD status provides Plus Therapeutics with incentives such as potential seven-year market exclusivity, tax credits for clinical trials, and regulatory fee exemptions.
This designation follows completion of the ReSPECT-LM Phase 1 trial, which established the recommended Phase 2 dose. Plus Therapeutics is advancing Phase 2 and Phase 1 multiple-dose trials and working with the FDA on a pivotal trial strategy.
Bambusa Therapeutics reports first patient dosed in proof-of-concept COPD trial
Kelun-Biotech lung cancer drug granted Breakthrough Therapy Designation in China
INOVIO's INO-3107 Biologics License Application accepted by US FDA
Sanofi and Regeneron's Dupixent gains Japan approval for paediatric asthma patients aged 6 to 11
Aqualung Therapeutics' Phase 2a lung fibrosis study approved by US FDA
Faron launches BLAZE trial with Institute of Cancer Research to address immunotherapy resistance
GSK agrees US pricing framework to expand access to respiratory medicines
Century Health partnerss with Tessel Biosciences to advance early drug development in COPD
Sanofi's efdoralprin alfa receives EU orphan designation for AATD-related emphysema